Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer

Autor: Michiel van de Ven, Maarten IJzerman, Valesca Retèl, Wim van Harten, Hendrik Koffijberg

Publikováno v: BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-12 (2022)

Abstract Background This study shows how dynamic simulation modeling can be applied in the context of the nationwide implementation of Whole Genome Sequencing (WGS) for non-small cell lung cancer (NSCLC) to inform organizational decisions regarding t

Externí odkaz: https://doaj.org/article/7a85232c28ff4b8eb54957899b030b87

Real-World Utilization of Biomarker Testing for Patients with Advanced Non–Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals

Autor: Hendrik Koffijberg, Valesca P. Retèl, Michiel van de Ven, Wim H. van Harten, Egbert F. Smit, Kim Monkhorst, Maarten Joost IJzerman

Publikováno v: Journal of Molecular Diagnostics, 23(4), 484-494. Elsevier Inc.
Journal of Molecular Diagnostics, 23(4), 484-494. Association of Molecular Pathology
The Journal of Molecular Diagnostics, 23(4), 484-494. ELSEVIER SCIENCE INC

The continued introduction of biomarkers and innovative testing methods makes already complex diagnosis in patients with stage IV nonesmall-cell lung cancer (NSCLC) even more complex. This study primarily analyzed variations in biomarker testing in c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2623a691f7c404ec17743df905b3512
https://doi.org/10.1016/j.jmoldx.2021.01.004

Early technology assessment of using whole genome sequencing in personalized oncology

Autor: Manuela A. Joore, Erik Koffijberg, Michiel van de Ven, Wim H. van Harten, Martijn Simons, Veerle M.H. Coupé, Edwin Cuppen, Geert W.J. Frederix, Maarten Joost IJzerman, Valesca P. Retèl, Carin Uyl-de Groot

Publikováno v: Simons, M, Van De Ven, M, Coupé, V, Joore, M, IJzerman, M, Koffijberg, E, Frederix, G, Uyl-De Groot, C, Cuppen, E, Van Harten, W & Retèl, V 2021, ' Early technology assessment of using whole genome sequencing in personalized oncology ', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 21, no. 3, pp. 343-351 . https://doi.org/10.1080/14737167.2021.1917386

Introduction: Personalized medicine-based treatments in advanced cancer hold the promise to offer substantial health benefits to genetic subgroups,but require efficient biomarker-based patient stratification to match the right treatment and may be ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf02d5f48e526f9c35b8c2a65fd7026e
https://zenodo.org/record/5054156

Real-World Utilization of Biomarker Testing for Patients with Advanced Non–Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals

Autor: Michiel van de Ven, Hendrik Koffijberg, Valesca Retèl, Kim Monkhorst, Egbert Smit, Maarten IJzerman

The continued introduction of biomarkers and innovative testing methods makes already complex diagnosis in patients with stage IV non–small-cell lung cancer (NSCLC) even more complex. This study primarily analyzed variations in biomarker testing in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2659::d975dccc08b3a3161210f68ee8fc4363
https://zenodo.org/record/4650681

PCN377 Where do we go with whole genome sequencing in oncology? Using scenario drafting to explore future developments

Autor: Willem H. van Harten, Martijn J. H. G. Simons, Maarten Joost IJzerman, Manuela A. Joore, Michiel van de Ven, Valesca P. Retèl, Erik Koffijberg

Publikováno v: Value in health, 22(Suppl. 3), S509-s510. Elsevier

OBJECTIVES: Whole genome sequencing (WGS) is a promising but complex technology. WGS is not yet widely used as a clinical diagnostic in oncology due to several barriers, such as the required infrastructure and expertise, costs, and unknown clinical u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3840e697493f50e5c8313f7164a1f851
https://doi.org/10.1016/j.jval.2019.09.572